This trial is active, not recruiting.

Conditions asthma, severe persistent asthma
Sponsor Wake Forest School of Medicine
Collaborator National Heart, Lung, and Blood Institute (NHLBI)
Start date December 2012
End date June 2017
Trial size 700 participants
Trial identifier NCT01750411, 1U10HL109164-01, SARP3, 1U10 HL109164-01


The mission of SARP is to improve the understanding of severe asthma through the integrated study of the effect of genetics on the clinical and biological features of asthma and to investigate how these change over time. The ultimate goal of these efforts is to promote better treatments for severe asthma.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Severe Asthma Not severe Asthma

Primary Outcomes

Change in pulmonary function over time
time frame: 36 months

Secondary Outcomes

Frequency of severe asthma exacerbations
time frame: 36 months

Eligibility Criteria

Male or female participants at least 6 years old.

Inclusion Criteria: 1. Physician diagnosis of asthma, 2. Age 6 years and older 3. Evidence of historical reversibility, including either: - FEV1 bronchodilator reversibility ≥ 12%, or - Airway hyperresponsiveness reflected by methacholine PC20≤16 mg/mL. Exclusion Criteria: 1. No primary medical caregiver 2. Pregnancy (only if undergoing methacholine challenge or bronchoscopy) 3. Current smoking 4. Smoking history > 10 pack years if ≥ 30 years of age or smoking history >5 pack years if < 30 years of age (Note: If a subject has a smoking history, no smoking within the past year) 5. Other chronic pulmonary disorders associated with asthma-like symptoms, including (but not limited to) cystic fibrosis, chronic obstructive pulmonary disease, chronic bronchitis, vocal cord dysfunction that is the sole cause of asthma symptoms, severe scoliosis or chest wall deformities that affect lung function, or congenital disorders of the lungs or airways 6. History of premature birth before 35 weeks gestation 7. Planning to relocate from the clinical center area before study completion

Additional Information

Official title The Severe Asthma Research Program at Wake Forest University - Longitudinal Phenomics and Genetics of Severe Asthma.
Principal investigator Eugene R Bleecker, MD
Description The mission of the SARP is to improve the understanding of severe asthma to develop better treatments. The SARP will gain a better understanding of asthma and its endotypes, in children and adults, by defining the disease at the molecular and cellular levels in the context of the temporal phenotypic expression of the disease. To this end, the SARP investigators will utilize both mechanistic and evoked phenotype approaches to: 1) characterize developmental molecular, cellular and physiologic phenotypes in children and adults with mild to severe asthma, and 2) to further elucidate the evolving pathobiology and pathogenesis of severe asthma and its sub-phenotypes and 3) compare these features over time. This approach involves a shared longitudinal protocol conducted across all participating centers which includes common information on all SARP participants. Additionally, SARP investigators have each identified mechanistic research questions to be included in the shared longitudinal protocol. At Wake Forest University investigators are specifically interested in genetic influences on disease severity and the use of statistical modeling techniques to better understand disease phenotypes. Together, these longitudinal and mechanistic approaches will enable prediction of phenotype stability/fluctuation and pharmacologic responses and identification of novel, disease-modifying targets for treatment.
Trial information was received from ClinicalTrials.gov and was last updated in June 2015.
Information provided to ClinicalTrials.gov by Wake Forest School of Medicine.